The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of...
Timothy S Leung,1 Ernest H Law2 1Faculty of Pharmaceutical Sciences, University of British Columbia...
BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases ...
BACKGROUND The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and...
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) i...
International audienceBACKGROUND: The direct oral thrombin inhibitor dabigatran has a predictable an...
Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be...
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF...
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is cau...
BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. ...
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in th...
Background Novel oral anticoagulants and warfarin are widely used for stroke prevention in patients ...
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, requires an ...
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monito...
Direct thrombin-inhibitors inactivate not only free but also fibrin-bound thrombin. The group of par...
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of...
Timothy S Leung,1 Ernest H Law2 1Faculty of Pharmaceutical Sciences, University of British Columbia...
BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases ...
BACKGROUND The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and...
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) i...
International audienceBACKGROUND: The direct oral thrombin inhibitor dabigatran has a predictable an...
Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be...
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF...
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is cau...
BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. ...
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in th...
Background Novel oral anticoagulants and warfarin are widely used for stroke prevention in patients ...
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, requires an ...
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monito...
Direct thrombin-inhibitors inactivate not only free but also fibrin-bound thrombin. The group of par...
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of...
Timothy S Leung,1 Ernest H Law2 1Faculty of Pharmaceutical Sciences, University of British Columbia...
BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases ...
DOI
Add to ORKG